Literature DB >> 22848250

Inhibitory effect of vitamin D-binding protein-derived macrophage activating factor on DMBA-induced hamster cheek pouch carcinogenesis and its derived carcinoma cell line.

Yukiyo Toyohara1, Susumu Hashitani, Hiromitsu Kishimoto, Kazuma Noguchi, Nobuto Yamamoto, Masahiro Urade.   

Abstract

This study investigated the inhibitory effect of vitamin D-binding protein-derived macrophage-activating factor (GcMAF) on carcinogenesis and tumor growth, using a 9,10-dimethyl-1,2-benzanthracene (DMBA)-induced hamster cheek pouch carcinogenesis model, as well as the cytocidal effect of activated macrophages against HCPC-1, a cell line established from DMBA-induced cheek pouch carcinoma. DMBA application induced squamous cell carcinoma in all 15 hamsters of the control group at approximately 10 weeks, and all 15 hamsters died of tumor burden within 20 weeks. By contrast, 2 out of the 14 hamsters with GcMAF administration did not develop tumors and the remaining 12 hamsters showed a significant delay of tumor development for approximately 3.5 weeks. The growth of tumors formed was significantly suppressed and none of the hamsters died within the 20 weeks during which they were observed. When GcMAF administration was stopped at the 13th week of the experiment in 4 out of the 14 hamsters in the GcMAF-treated group, tumor growth was promoted, but none of the mice died within the 20-week period. On the other hand, when GcMAF administration was commenced after the 13th week in 5 out of the 15 hamsters in the control group, tumor growth was slightly suppressed and all 15 hamsters died of tumor burden. However, the mean survival time was significantly extended. GcMAF treatment activated peritoneal macrophages in vitro and in vivo, and these activated macrophages exhibited a marked cytocidal effect on HCPC-1 cells. Furthermore, the cytocidal effect of activated macrophages was enhanced by the addition of tumor-bearing hamster serum. These findings indicated that GcMAF possesses an inhibitory effect on tumor development and growth in a DMBA-induced hamster cheek pouch carcinogenesis model.

Entities:  

Year:  2011        PMID: 22848250      PMCID: PMC3406437          DOI: 10.3892/ol.2011.306

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  35 in total

1.  Activation of macrophages by ether analogues of lysophospholipids.

Authors:  N Yamamoto; B Z Ngwenya; T W Sery; R A Pieringer
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

2.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

3.  Activation process of macrophages after in vitro treatment of mouse lymphocytes with dodecylglycerol.

Authors:  S Homma; N Yamamoto
Journal:  Clin Exp Immunol       Date:  1990-02       Impact factor: 4.330

Review 4.  Immunological factors which influence response to immunotherapy in malignant melanoma.

Authors:  D Morton; F R Eilber; R A Malmgren; W C Wood
Journal:  Surgery       Date:  1970-07       Impact factor: 3.982

5.  Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens.

Authors:  S Zhang; H S Zhang; C Cordon-Cardo; V E Reuter; A K Singhal; K O Lloyd; P O Livingston
Journal:  Int J Cancer       Date:  1997-09-26       Impact factor: 7.396

6.  Increased expression of cyclooxygenase (COX)-2 in DMBA-induced hamster cheek pouch carcinogenesis and chemopreventive effect of a selective COX-2 inhibitor celecoxib.

Authors:  Norihiko Nishimura; Masahiro Urade; Susumu Hashitani; Kazuma Noguchi; Yukiyo Manno; Kazuki Takaoka; Kazunari Sakurai
Journal:  J Oral Pathol Med       Date:  2004-11       Impact factor: 4.253

7.  An epidermoid carcinoma cell line derived from hamster 7,12-dimethylbenz[a]anthracene-induced buccal pouch tumors.

Authors:  O Odukoya; J Schwartz; R Weichselbaum; G Shklar
Journal:  J Natl Cancer Inst       Date:  1983-12       Impact factor: 13.506

8.  Vitamin D3 binding protein required for in vitro activation of macrophages after alkylglycerol treatment of mouse peritoneal cells.

Authors:  N Yamamoto; S Homma; J G Haddad; M A Kowalski
Journal:  Immunology       Date:  1991-11       Impact factor: 7.397

9.  Effects of inflammation products on immune systems. Lysophosphatidylcholine stimulates macrophages.

Authors:  B Z Ngwenya; N Yamamoto
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

10.  Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF.

Authors:  Nobuto Yamamoto; Hirofumi Suyama; Hiroaki Nakazato; Nobuyuki Yamamoto; Yoshihiko Koga
Journal:  Cancer Immunol Immunother       Date:  2008-07       Impact factor: 6.968

View more
  2 in total

1.  A novel role for a major component of the vitamin D axis: vitamin D binding protein-derived macrophage activating factor induces human breast cancer cell apoptosis through stimulation of macrophages.

Authors:  Lynda Thyer; Emma Ward; Rodney Smith; Maria Giulia Fiore; Stefano Magherini; Jacopo J V Branca; Gabriele Morucci; Massimo Gulisano; Marco Ruggiero; Stefania Pacini
Journal:  Nutrients       Date:  2013-07-08       Impact factor: 5.717

2.  Analysis of the Biological Properties of Blood Plasma Protein with GcMAF Functional Activity.

Authors:  Evgeniya V Dolgova; Svetlana S Kirikovich; Evgeniy V Levites; Vera S Ruzanova; Anastasia S Proskurina; Genrikh S Ritter; Oleg S Taranov; Nikolay A Varaksin; Tatiana G Ryabicheva; Olga Yu Leplina; Alexandr A Ostanin; Elena R Chernykh; Sergey S Bogachev
Journal:  Int J Mol Sci       Date:  2022-07-22       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.